Dixon Mitchell Investment Counsel’s ARK Genomic Revolution ETF ARKG Stock Holding History

Dixon Mitchell Investment Counsel’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-170	Closed	-$3.53K	–	73
2025 Q1	$3.53K	Hold	170	–	–	﹤0.01%	88
2024 Q4	$4K	Hold	170	–	–	﹤0.01%	109
2024 Q3	$4.35K	Hold	170	–	–	﹤0.01%	87
2024 Q2	$3.99K	Hold	170	–	–	﹤0.01%	124
2024 Q1	$4.89K	Buy	+170	New	+$5.11K	﹤0.01%	161

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dixon Mitchell Investment Counsel's ARKG Position: Q2 2025 in Review

Dixon Mitchell Investment Counsel sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2025, closing a stake of 170 shares — an estimated $3.53K sold.

Dixon Mitchell Investment Counsel first reported a position in ARKG in Q1 2024 and held it in 5 quarters. The position peaked at $4.89K in Q1 2024. 213 funds tracked by Wall St. Rank hold ARKG as of Q2 2025.

Dixon Mitchell Investment Counsel reported no remaining ARK Genomic Revolution ETF position as of Q2 2025 after selling out during the quarter.
Dixon Mitchell Investment Counsel sold 170 ARK Genomic Revolution ETF shares in Q2 2025, an estimated $3.53K.
Dixon Mitchell Investment Counsel first reported a position in ARK Genomic Revolution ETF in Q1 2024 and held it in 5 quarters.
Dixon Mitchell Investment Counsel's ARK Genomic Revolution ETF position peaked at $4.89K in Q1 2024.
213 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2025.

Based on Dixon Mitchell Investment Counsel's 13F filing for Q2 2025, filed 13 Aug 2025.